There have been many recent advances in HER2-targeted therapies, including trastuzumab (T), lapatinib (L), pertuzumab (P), and trastuzumab emtansine (T-DM1), which have significantly improved the progression and overall survival outcomes for HER2+ve breast cancer patients [2,3]. Here, ERBB2 is linked to breast cancer.